iA Global Asset Management Inc. Acquires Shares of 7,174 Edwards Lifesciences Corporation $EW

iA Global Asset Management Inc. bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 7,174 shares of the medical research company’s stock, valued at approximately $574,000.

A number of other institutional investors have also modified their holdings of the business. Hanson & Doremus Investment Management acquired a new stake in shares of Edwards Lifesciences during the first quarter worth about $25,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter worth about $25,000. MV Capital Management Inc. acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $27,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $28,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

EW has been the topic of several analyst reports. BTIG Research lifted their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a research note on Tuesday. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $100.00 price target on shares of Edwards Lifesciences in a report on Tuesday, June 16th. Truist Financial set a $90.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Barclays restated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Robert W. Baird lifted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $96.39.

Edwards Lifesciences Stock Performance

Shares of EW opened at $94.31 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $94.47. The company has a 50-day simple moving average of $85.35 and a 200-day simple moving average of $83.49. The company has a market capitalization of $54.31 billion, a PE ratio of 50.17, a P/E/G ratio of 2.31 and a beta of 0.86.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the previous year, the firm earned $0.64 earnings per share. The firm’s revenue was up 16.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Equities research analysts predict that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,177,507.96. The trade was a 24.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 58,977 shares of company stock worth $4,921,803. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.